A landmark ruling against Novartis highlights practices that make healthcare unaffordable in developing countries BY MICHELLE CHEN, DISSENT MAGAZINE (Credit: AP Photo/Rogelio V. Solis, File) This article was originally published by Dissent. As our television screens toggle between pundits squabbling over Obamacare’s… Continue Reading →
In the backdrop of the Supreme Court judgment against Novartis trying to seek patent on its anticancer drug Gleevec used for treatment of CML and the granting of license to pharmaceutical company Natco by the Controller General of Patents India… Continue Reading →
Expectations of structural change and divestments will be reignited by the Symonds announcement, note analysts at Deutsche Bank. One particular conundrum for investors is the 33 percent shareholding that Novartis holds in its compatriot Roche. Jimenez has ascribed an… Continue Reading →
4 May 2013 A portrait of a fearless piece of Indian legislation that assures affordable medication to the world’s poor BY Achal Prabhala, Sudhir Krishnaswamy , Open Magazine NEED FOR CHEAP DRUGS: Cancer patient Siddhart Maske seated outside the Tata cancer hospital in… Continue Reading →
Professor Brook K. Baker, Senior Policy Analyst Health GAP April 2, 2013, IP Novartis, its fellow Big Pharma multinationals, Chambers of Commerce, and PhRMA have all roundly denounced India’s Supreme Court’s decision invalidating Novartis’ patent application for Glivec (Gleevec in… Continue Reading →
APRIL 2, 2013 BY RAMANAN50 The instances of Multinationals stealing indigenous medicines is well-known. So are the capricious overpricing of life saving Drugs, like Cancer Drugs. “ The Intellectual Property Appellate Board rejected the German drug maker’s appeal of the 2012 ruling on Monday. It also ruled… Continue Reading →
Anand Grover | Apr 2, 2013, After 2005 India started granting product patents on medicines. However, Section S ection 3(d), one of the safeguards introduced by Parliament, seeks to prevent patenting of new forms of known substances unless they exhibit enhanced efficacy…. Continue Reading →
Vidya Krishnan , livemint Court says Glivec does not meet any standard of ‘novelty or inventiveness’ to qualify for a patent First Published: Mon, Apr 01 2013. Shares of Novartis India fell as much as 7% after the Supreme Court judgement. The… Continue Reading →
WEB EXCLUSIVE, New International Oct , 2012 Cases being heard in Indian courts could ‘open the floodgates’ for pharmaceutical companies to challenge generic drug production and keep prices ridiculously high, explains Nick Harvey. It’s a worrying time for the poor and… Continue Reading →
© 2023 Kractivism — Powered by WordPress
Theme by Anders Noren — Up ↑